Navigation Links
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Date:7/23/2009

p=0.058 ---------- ----- ----- ------- Erosion Score +0.94 +0.78 p=0.62 ------------- ----- ----- ------ * RAMRIS is a rheumatoid arthritis scoring system utilizing magnetic resonance imaging to evaluate abnormalities (synovitis, bone edema and bone erosion) in the hands and wrists. The system was developed by OMERACT, (Outcome Measurements in Rheumatology) in 2002, and has become a global standard measurement of inflammation and destruction in those joints. For these scores a lower value indicates a better clinical condition. ** Synovitis: inflammation of the synovial membrane lining joints Osteitis: inflammation of the bone

Safety Results

Similar to TASKi2, the most common clinically meaningful drug-related adverse events noted in TASKi3 were diarrhea and hypertension. Dose reduction options were pre-specified in the trial protocol and, in cases where doses were reduced, patients generally completed the clinical trial with minimal safety issues. The most common adverse events in the trial overall were related to infections, though these were generally evenly distributed among the placebo and active dose group.

The mean increase in blood pressure from baseline at 3 months, using a last observation carry forward methodology, was 3.2-3.6 mmHg for the 100 mg bid dose group. In TASKi3, approximately 17% of patients in the 100 mg bid dose group had blood pressure medication adjusted or in some cases initiated during the course of the clinical trial, compared to 8% of the placebo patients. For those patients who had their dose of blood pressure medications adjusted or initiated, their blood pressure was successfully reduced and their blood pressure was generally well controlled throughout the trial. The blood pressure medications were standard doses of commo
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
(Date:1/23/2015)...  HyGreen, Inc., a leader in hand hygiene monitoring, today ... a subsidiary of Ascendis Health Limited, in ... hundreds of millions of patients around the world are ... from patient to patient via the unwashed hands of ...
(Date:1/23/2015)... , Jan. 23, 2015 Cord Blood America, Inc. ( ... or the "Company")  filed a Preliminary Proxy Statement, Schedule 14A, ... today, and provides an update for shareholders detailing why a ... requested. Dear Shareholders, As we reflect ...
Breaking Medicine Technology:Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3HyGreen Partners with RCA Medical in Johannesburg, South Africa 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 2Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 3Cord Blood America Announces Preliminary Proxy Filing and Details Why a "YES" Vote to Increase Authorized Shares Is Requested 4
... CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ --,Nuvelo, Inc. ... data from the Anthem (Anticoagulation with rNAPc2,To Help ... June,26th issue of the Journal of of Cardiology ... 7.5 mcg/kg) recombinant,nematode anticoagulant protein c2 (rNAPc2) reduced ...
... June 15 /CNW/ - Today AMADEO, one of the,first ... receptor blockers in hypertensive patients with,diabetic nephropathy, was ... results from this study show that ,telmisartan reduces proteinuria ... , ,Commenting on the results, ...
Cached Medicine Technology:Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 2New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 3New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 4New Study Shows That telmisartan has Greater Renoprotective,Potential Thanlosartan in Hypertensive Patients With Type 2,Diabetes 5
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A ... Sports Medicine flagship journal Medicine & Science in ... before exercise may help reduce gastrointestinal (GI) problems ... , Participants in the double-blind, placebo-controlled study ...
(Date:1/22/2015)... Payday lending practices in four southern states ... distress to the states that permit them, according to ... on Race and Wealth. , While they generate hundreds ... at the same time substantially depress economic activity, according ...
(Date:1/22/2015)... Lower-Auto-Insurance.com has released a new blog post explaining the importance ... reducing the costs of an auto insurance policy . , ... lower prices for their vehicle insurance policies. The safety a vehicle ... costs. Because of this, drivers should always carry a first ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Nov. 1 To mark the start of,American Diabetes ... to adopt healthy habits that may help them to ... disease that affects an estimated 21 million,Americans including more ... serious, public health concern with causes linked to,both genetics ...
... Minn., Nov. 1 Otter Tail,Corporation (Nasdaq: OTTR ) announced ... highlights: -- Record third quarter revenues of $302.2 million. ... of 2007 compared with $13.5 million for ... of $0.44 for the third quarter of 2007 ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a ... cardiovascular disease, is scheduled to participate in the,Southern ... Newport,Beach, California on Wednesday, November 7, 2007. ... Investor,Relations, is scheduled to speak to conference attendees ...
... HAYWARD, Calif., Nov. 1 Acologix, Inc., a ... Dawn,McGuire, M.D. as its Chief Medical Officer. As ... of executive leadership in drug,development, including roles as ... McGuire brings substantial expertise in therapeutic,product development for ...
... 1 Thousands of public,health professionals will meet ... and address the nation,s most pressing public health ... Annual Meeting., The five-day meeting of more ... is expected to draw around 14,000,public health researchers, ...
... Nov. 1 Vital Images, Inc.,(Nasdaq: VTAL ), ... will present at the CIBC World,Markets 18th Annual Healthcare ... a.m. ET). Jay D. Miller, president and chief executive,officer, ... To access the Webcast, go to the investors, section ...
Cached Medicine News:Health News:Health Secretary Promotes Awareness of Diabetes, Urges Healthy Habits 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 2Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 3Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 4Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 5Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 6Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 7Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 8Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 9Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 10Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 11Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 12Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 13Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 14Health News:Otter Tail Corporation Announces Third Quarter Earnings and Maintains 2007 Earnings Guidance; Board of Directors Declares Dividend 15Health News:Edwards Lifesciences to Present at the Southern California Investor Conference 2Health News:Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer 2Health News:Dawn McGuire, M.D. Joins Acologix, Inc. as Chief Medical Officer 3Health News:14,000 Public Health Experts to Convene at American Public Health Association Annual Meeting in Washington, D.C. 2Health News:14,000 Public Health Experts to Convene at American Public Health Association Annual Meeting in Washington, D.C. 3Health News:Vital Images to Present at the CIBC World Markets 18th Annual Healthcare Conference on Wednesday, November 7 2
... Designed in collaboration with Dr. George ... the Ojemann Cortical Stimulator is the ... procedures. This portable, constant current unit ... settings suitable for use in the ...
... Integra Epilepsy cortical strip electrodes are ... intracranial placement through a burr hole. ... tunneling and enables quick and secure ... Like all Integra Epilepsy electrode designs, ...
...
... URISYS 2400 is designed for laboratories looking ... and convenience in system operation in terms ... and extended calibration and on-board stability., ... system providing enhanced walk-away capability for medium ...
Medicine Products: